BiotechTube
PhosphoGam

PhosphoGam

San Diego, United States· Est.
phosphogam.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

PhosphoGam is a private, preclinical-stage biotech based in Durham, NC, pioneering a novel approach to allogeneic CAR-T. Its core innovation is a proprietary small-molecule platform for the limitless, consistent, and economical expansion of fit γδ-T cells from healthy donors, which are then engineered using non-viral mRNA electroporation to create CAR-T products. The company's strategy emphasizes re-dosing, enhanced tumor-homing, and transient persistence to improve efficacy and safety while achieving massive scale. Backed by a leading biotech VC, PhosphoGam aims to address the major limitations of cost, scale, and solid tumor penetration in current cell therapies.

Oncology

Technology Platform

Proprietary small-molecule platform for limitless expansion of fit gamma/delta-T (γδ-T) cells from healthy donors, combined with non-viral CAR-T engineering via mRNA electroporation. Enables allogeneic, off-the-shelf CAR-T with novel re-dosing and tumor-homing strategies.

Opportunities

PhosphoGam targets the massive unmet need in solid tumor oncology and the scalability/cost limitations of current autologous CAR-T.
Its claimed 90% lower manufacturing cost and ability to treat tens of thousands annually from one site could democratize cell therapy access.
The platform's rapid R&D cycle allows for quick generation of new candidates against various targets.

Risk Factors

The technology is preclinical and unproven in humans; its novel zero-persistence/re-dosing strategy carries clinical validation risk.
The company operates in the highly competitive allogeneic CAR-T space against well-funded rivals.
As a small, private firm, it is dependent on raising additional capital to reach clinical milestones.

Competitive Landscape

PhosphoGam competes in the allogeneic CAR-T space with companies like Allogene Therapeutics, Caribou Biosciences, and CRISPR Therapeutics, which often use gene-editing (e.g., CRISPR, TALEN) to overcome host rejection. Its differentiation lies in using unedited γδ-T cells for inherent allogeneic properties, non-viral mRNA engineering, and a focus on manufacturing economics and solid tumors via enhanced homing.

More companies in Cell & Gene Therapy →More companies in United States →